Primary systemic amyloidosis

Archana Roy, Vivek Roy

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Primary systemic amyloidosis is a rare disease with protean manifestations. Presence of nephrotic syndrome in the absence of diabetes and hypertension, cardio-myopathy in the absence of isch-emia, restrictive cardiac defect, demyelinating polyneuropathy, or unexplained hepatomegaly should alert the physician to the possibility of amyloidosis. Initial steps in the diagnostic evaluation of patients with suspected amyloidosis include serum and urine immunoelectrophoresis and immunofixation studies. Demonstration of amyloid material on tissue biopsy (eg, subcutaneous fat) is required for diagnosis. Availability of effective treatments has improved the outlook of patients with primary systemic amyloidosis. Early diagnosis is critical to optimizing the chances of effective therapy.

Original languageEnglish (US)
JournalPostgraduate Medicine
Volume119
Issue number1
DOIs
StatePublished - Jan 1 2006

Fingerprint

Amyloidosis
Immunoelectrophoresis
Hepatomegaly
Polyneuropathies
Subcutaneous Fat
Nephrotic Syndrome
Muscular Diseases
Rare Diseases
Amyloid
Early Diagnosis
Urine
Hypertension
Physicians
Biopsy
Therapeutics
Serum
Primary amyloidosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Primary systemic amyloidosis. / Roy, Archana; Roy, Vivek.

In: Postgraduate Medicine, Vol. 119, No. 1, 01.01.2006.

Research output: Contribution to journalReview article

Roy, Archana ; Roy, Vivek. / Primary systemic amyloidosis. In: Postgraduate Medicine. 2006 ; Vol. 119, No. 1.
@article{75fe976a957c4706a1f13e3f06c95d9d,
title = "Primary systemic amyloidosis",
abstract = "Primary systemic amyloidosis is a rare disease with protean manifestations. Presence of nephrotic syndrome in the absence of diabetes and hypertension, cardio-myopathy in the absence of isch-emia, restrictive cardiac defect, demyelinating polyneuropathy, or unexplained hepatomegaly should alert the physician to the possibility of amyloidosis. Initial steps in the diagnostic evaluation of patients with suspected amyloidosis include serum and urine immunoelectrophoresis and immunofixation studies. Demonstration of amyloid material on tissue biopsy (eg, subcutaneous fat) is required for diagnosis. Availability of effective treatments has improved the outlook of patients with primary systemic amyloidosis. Early diagnosis is critical to optimizing the chances of effective therapy.",
author = "Archana Roy and Vivek Roy",
year = "2006",
month = "1",
day = "1",
doi = "10.3810/pgm.2006.06.1652",
language = "English (US)",
volume = "119",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "1",

}

TY - JOUR

T1 - Primary systemic amyloidosis

AU - Roy, Archana

AU - Roy, Vivek

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Primary systemic amyloidosis is a rare disease with protean manifestations. Presence of nephrotic syndrome in the absence of diabetes and hypertension, cardio-myopathy in the absence of isch-emia, restrictive cardiac defect, demyelinating polyneuropathy, or unexplained hepatomegaly should alert the physician to the possibility of amyloidosis. Initial steps in the diagnostic evaluation of patients with suspected amyloidosis include serum and urine immunoelectrophoresis and immunofixation studies. Demonstration of amyloid material on tissue biopsy (eg, subcutaneous fat) is required for diagnosis. Availability of effective treatments has improved the outlook of patients with primary systemic amyloidosis. Early diagnosis is critical to optimizing the chances of effective therapy.

AB - Primary systemic amyloidosis is a rare disease with protean manifestations. Presence of nephrotic syndrome in the absence of diabetes and hypertension, cardio-myopathy in the absence of isch-emia, restrictive cardiac defect, demyelinating polyneuropathy, or unexplained hepatomegaly should alert the physician to the possibility of amyloidosis. Initial steps in the diagnostic evaluation of patients with suspected amyloidosis include serum and urine immunoelectrophoresis and immunofixation studies. Demonstration of amyloid material on tissue biopsy (eg, subcutaneous fat) is required for diagnosis. Availability of effective treatments has improved the outlook of patients with primary systemic amyloidosis. Early diagnosis is critical to optimizing the chances of effective therapy.

UR - http://www.scopus.com/inward/record.url?scp=33746544154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746544154&partnerID=8YFLogxK

U2 - 10.3810/pgm.2006.06.1652

DO - 10.3810/pgm.2006.06.1652

M3 - Review article

VL - 119

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 1

ER -